Press Releases

Archives: Search / 2017

2016201520142013201220112010200920082007

2010 Archives

Mar 30, 2010

Eisai Inc. today announced that it has submitted simultaneous regulatory applications for approval of eribulin mesylate (also known as E7389) for the treatment of locally advanced or metastatic...

More
Mar 25, 2010

Eisai Inc. announced today that the Phase III ACCESS (A Controlled Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial of the investigational compound eritoran (E5564) will...

More
Mar 12, 2010

Eisai Inc. (Headquarters: Woodcliff Lake, New Jersey, Chairman and CEO: Hajime Shimizu, "Eisai") today announces that it has entered into a licensing agreement with the Johns Hopkins University's...

More
Mar 11, 2010

Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic...

More
Jan 19, 2010
The DVTeamCare™ Hospital Award Provides National Recognition for Deep Vein Thrombosis Prevention Programs

The North American Thrombosis Forum (NATF), in coordination with Eisai Inc., announced today that three hospitals have been selected as recipients of the 2009 DVTeamCare Hospital Award. This new...

More
Jan 6, 2010

Eisai Inc. (Headquarters: Woodcliff Lake, New Jersey, Chairman and CEO: Hajime Shimizu, "Eisai") today announces the successful completion of its acquisition of the biopharmaceutical company,...

More
 

print email rss